Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase

• Published in: Immunity (Cambridge, Mass.) Vol. 57; no. 3; pp. 574 - 586.e7
• Main Authors: Lederhofer, Julia, Tsybovsky, Yaroslav, Nguyen, Lam, Raab, Julie E., Creanga, Adrian, Stephens, Tyler, Gillespie, Rebecca A., Syeda, Hubza Z., Fisher, Brian E., Skertic, Michelle, Yap, Christina, Schaub, Andrew J., Rawi, Reda, Kwong, Peter D., Graham, Barney S., McDermott, Adrian B., Andrews, Sarah F., King, Neil P., Kanekiyo, Masaru
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 12.03.2024
• Subjects: Animals; Antibodies, Monoclonal; Antibodies, Viral; antigenic site; B cell; bnab; cryo-EM; dark side; epitope; human monoclonal antibody; Humans; influenza; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; mAb; Mice; Neuraminidase; Orthomyxoviridae Infections; Swine; underside; Viral Proteins - genetics; influenza; B cell; dark side; NA; bnab; underside; neuraminidase; antigenic site; epitope; cryo-EM; human monoclonal antibody; mAb

Continuously evolving influenza viruses cause seasonal epidemics and pose global pandemic threats. Although viral neuraminidase (NA) is an effective drug and vaccine target, our understanding of the NA antigenic landscape still remains incomplete. Here, we describe NA-specific human antibodies that...